Pfizer Inc (PFE) 30.08 $PFE
Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - Fri Mar 25, 8:00PM CDT
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 254.69 (-0.55), VRX: 31.09 (-2.34), WMT: 68.00 (+0.54), INTC: 31.88 (-0.12), SHLD: 15.00 (+0.04), AGN: 279.32 (-1.99), SBUX: 58.36 (-0.47), JACK: 63.12 (+0.02), JNJ: 108.31 (-0.19), DNKN: 45.32 (-0.21), IBM: 147.95 (+2.55), CMG: 471.37 (-3.09), ABBV: 56.12 (-0.24), SNY: 38.87 (-0.53), KKD: 14.61 (+0.32), REGN: 370.80 (+5.42), HD: 130.46 (+0.24), PFE: 30.08 (-0.11), LLY: 71.12 (-0.05), GSK: 39.56 (+0.19), BMY: 62.52 (+0.18), PLKI: 51.07 (+0.98), DIN: 92.00 (-1.02), CELG: 100.54 (+0.62), QSR: 37.63 (-0.38), GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), AZN: 28.00 (-0.01), MCD: 123.29 (-0.90), WEN: 10.42 (+0.06)
10 Women Who Would Be a Great Addition to Any Company's Board
at The Street - Thu Mar 24, 12:03PM CDT
Seven companies in the S&P 500 have no women on their boards. Maybe they're having trouble finding the right women? We aren't. Here are 10 that would make great additions.
CXO: 103.61 (+2.07), HST: 16.18 (unch), MDLZ: 39.51 (-0.43), HON: 111.32 (-0.89), CAH: 81.48 (+0.20), KORS: 55.53 (-0.40), IDA: 74.11 (+0.08), DO: 21.96 (+0.06), AMAT: 20.15 (-0.13), EOG: 74.30 (-0.04), MSFT: 54.21 (+0.24), REV: 35.99 (+0.50), MU: 10.50 (-0.15), HAR: 85.66 (+0.57), SWKS: 76.20 (-0.10), PFE: 30.08 (-0.11), MCHP: 48.12 (+0.16), LLTC: 44.26 (+0.14), UL: 44.63 (+0.03), MGM: 20.52 (-0.24), CELG: 100.54 (+0.62), GILD: 91.32 (+1.24), TXN: 56.70 (+0.10), MRK: 53.07 (-0.01), QLGC: 13.01 (+0.12), ADI: 58.64 (+0.31), MRO: 10.29 (+0.10), CVX: 94.85 (+1.26), XRAY: 59.62 (-0.93), NVS: 73.30 (-0.61), GRMN: 38.97 (-0.36), CCE: 49.59 (-0.21), K: 75.44 (+0.40), JNPR: 25.36 (-0.28), IBM: 147.95 (+2.55), APA: 48.85 (+0.99), GOOGL: 754.84 (-2.72), TER: 21.09 (+0.03), ALGN: 70.23 (+0.45), MET: 42.30 (-1.11), DISCA: 27.99 (+0.18), FCAU: 7.62 (-0.15), ISIL: 13.21 (+0.18), ORCL: 40.97 (+0.22), SQ: 12.88 (+0.29), GS: 153.00 (-1.08), QRVO: 49.24 (-0.28), LRCX: 78.88 (-0.48), BAX: 40.11 (-0.58), GM: 30.96 (-0.35), CRUS: 34.47 (-0.11), PG: 82.89 (+0.07), AVGO: 153.00 (+0.01), GSBD: 19.89 (unch), CRM: 72.44 (+0.66)
The 3 Best Stocks to Own in Retirement
Todd Campbell, Sean Williams, and Steve Symington, The Motley Fool - Motley Fool - Thu Mar 24, 10:03AM CDT
Image source: Pixabay. Retirees are living longer than ever before, and that means retirees are focusing their portfolios less on slow-growth Treasury bonds and more on stocks so they don't outlive their savings. While stocks can add some punch to...
PFE: 30.08 (-0.11), VZ: 53.56 (+0.65), AFL: 62.70 (-0.70)
Pfizer's Revised Filing for Xeljanz Accepted for Review in EU
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 9:20AM CDT
Pfizer (PFE) had resubmitted the Marketing Authorization Application (MAA) for Xeljanz, which was accepted for review by the European Medicines Agency.
EBS: 33.75 (+0.60), PFE: 30.08 (-0.11), AMAG: 21.42 (+0.74), ANIK: 44.00 (-0.74)
If It Wasn't For Pfizer, Allergan Investors Might Be Getting Pummeled
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:21AM CDT
SOURCE: FLICKR USER STOCKMONKEYS.COM The unraveling of its buy-reprice-relaunch strategy has led to shares in Valeant Pharmaceuticals crumbling 80% in the past year, but Valeant Pharmaceuticals is far from the only publicly traded biopharma...
AGN: 279.32 (-1.99), VRX: 31.09 (-2.34), PFE: 30.08 (-0.11), HZNP: 16.02 (-0.30), TEVA: 54.29 (+0.24), DEPO: 13.31 (+0.17)
Portola Pharmaceuticals' Betrixaban Misses Mark, But All Is Not Lost
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:14AM CDT
SOURCE: PORTOLA PHARMACEUTICALS Portola Pharmaceuticals ' 7,513 person head to head study evaluating its next-generation anticoagulant betrixaban against standard of care Lovenox in the prevention of blood clots missed its endpoint in one trial...
JNJ: 108.31 (-0.19), PTLA: 20.27 (-8.35), PFE: 30.08 (-0.11), BMY: 62.52 (+0.18), SNY: 38.87 (-0.53)
Allergan Is a Good Buy for Investors, With or Without Pfizer
at The Street - Thu Mar 24, 7:38AM CDT
The Irish pharmaceutical company is launching a blockbuster drug, and its share price seems primed for a rebound.
AGN: 279.32 (-1.99), PFE: 30.08 (-0.11)
Pfizer Announces European Medicines Agency Accepted for Review Its Marketing Authorization Application for XELJANZ(R) (Tofacitinib Citrate) for the Treatment of Moderate to Severe Rheumatoid Arthritis
Business Wire - Wed Mar 23, 3:15PM CDT
Pfizer Inc. (NYSE
FE) announced today that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for XELJANZ(R) (tofacitinib citrate) 5 mg tablets twice daily for the treatment of patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). The EMA will now initiate its review of the XELJANZ MAA.
PFE: 30.08 (-0.11)
Follicular Thyroid Cancer - Pipeline Review, H1 2016 Featuring Exelixis, Inc., Genzyme Corporation, Novartis AG & Pfizer Inc. - Research and Markets
Business Wire - Wed Mar 23, 1:09PM CDT
Research and Markets (http://www.researchandmarkets.com/research/3v53qr/follicular) has announced the addition of the "Follicular Thyroid Cancer - Pipeline Review, H1 2016" report to their offering.
PFE: 30.08 (-0.11), NVS: 73.30 (-0.61), EXEL: 4.04 (+0.07)
Novartis Stock Downgraded: 3 Things You Need to Know
Rich Smith, The Motley Fool - Motley Fool - Wed Mar 23, 12:00PM CDT
With its stock down 26% in 52 weeks, German pharmaceutical giant Novartis is looking cheap and winning fans on Wall Street. But Leerink Partners is not one of them. According to data from S&P Global Market Intelligence , 16 out of 34...
JNJ: 108.31 (-0.19), PFE: 30.08 (-0.11), NVS: 73.30 (-0.61)
Stocks Run in Place as Brussels Attack Paralyzes Wall Street
at The Street - Tue Mar 22, 3:09PM CDT
A quieter holiday trading week was disrupted by tragedy on Tuesday, with dual explosions at a Brussels airport and metro station reigniting global concerns about terrorism.
VRX: 31.09 (-2.34), DAL: 47.84 (-1.07), PFE: 30.08 (-0.11), DB: 17.54 (-0.46), LL: 13.15 (+0.61), PCLN: 1,301.19 (-4.92), CELG: 100.54 (+0.62), UAL: 57.84 (-1.90), LUV: 44.06 (-0.37), GILD: 91.32 (+1.24), EXPE: 107.69 (-1.30), AAL: 40.50 (-1.42), AAPL: 105.67 (-0.46), IHG: 39.52 (+0.12)
Stock Market News for March 22, 2012
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 9:10AM CDT
Gains in healthcare and telecom stocks helped the benchmarks end marginally higher on Monday.
IHS: 119.57 (-1.43), FBHS: 54.56 (-0.09), PFE: 30.08 (-0.11), MRKT: 34.31 (+0.73), AMGN: 149.24 (+0.48), MAR: 68.64 (-0.96), HOT: 82.13 (-0.54), AGN: 279.32 (-1.99), T: 38.88 (+0.34), LEN: 46.35 (+0.15), GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), PHM: 17.91 (-0.07), OC: 47.00 (+0.30), VZ: 53.56 (+0.65)
Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts
Business Wire - Tue Mar 22, 9:00AM CDT
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 3, 2016. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2016 Performance Report, to be issued that morning.
PFE: 30.08 (-0.11)
Which Big Pharma Is the Best Dividend Stock?
Keith Speights, The Motley Fool - Motley Fool - Tue Mar 22, 8:12AM CDT
Image Source: LENDINGMEMO.COM . Big pharmaceutical firms have been a popular choice for dividend-seeking investors for a long time. Several pay out attractive and reliable dividends, and they throw in some opportunities for growth to boot. But...
PFE: 30.08 (-0.11), AZN: 28.00 (-0.01), ABBV: 56.12 (-0.24), GSK: 39.56 (+0.19), SNY: 38.87 (-0.53)
Pfizer Joins The Human Vaccines Project To Help Decode The Immune System
Business Wire - Tue Mar 22, 7:30AM CDT
Pfizer Inc. (NYSE FE) today announced it will join the Human Vaccines Project (the Project), a public-private consortium focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection. Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV and other infectious illnesses as well as cancer.
PFE: 30.08 (-0.11)
Why Amgen Is the Best S&P 500 Company
at The Street - Tue Mar 22, 7:24AM CDT
Bill Smead, chief investment officer and CEO of Smead Capital Management, sees opportunities in Amgen, which is his top holding.
JNJ: 108.31 (-0.19), GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), PFE: 30.08 (-0.11), AMGN: 149.24 (+0.48)
Celgene & Pfizer Present Data from Ulcerative Colitis Trials
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 12:20PM CDT
Celgene (CELG) and Pfizer (PFE) have presented data from their ulcerative colitis study at the 11th Congress of the European Crohn's and Colitis Organisation.
PFE: 30.08 (-0.11), HZNP: 16.02 (-0.30), ANIK: 44.00 (-0.74), CELG: 100.54 (+0.62)
SmarTrend Watching for Potential Pullback in Shares of Pfizer After 1.21% Gain
Comtex SmarTrend(R) - Mon Mar 21, 12:11PM CDT
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $29.44 to a high of $29.87. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $29.65 on volume of 12.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PFE: 30.08 (-0.11)
After Yesterday's Rally of 1.21% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 21, 12:09PM CDT
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $29.44 to a high of $29.87. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $29.65 on volume of 12.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PFE: 30.08 (-0.11)
2 Large-Cap Dividend Favorites and 5 Stocks to Avoid Based on Charts
at The Street - Sun Mar 20, 11:00AM CDT
Recently, TheStreet highlighted Deutsche Bank's top large-cap dividend stocks from a fundamental perspective. Today in-house chartist Bruce Kamich takes a technical look.
CCI: 85.58 (-0.08), PFE: 30.08 (-0.11), IVZ: 30.33 (-0.07), WDC: 48.12 (-0.60), PLD: 42.32 (+0.14), HPQ: 12.07 (+0.05), CSCO: 27.96 (+0.13)
Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - Fri Mar 25, 8:00PM CDT
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 254.69 (-0.55), VRX: 31.09 (-2.34), WMT: 68.00 (+0.54), INTC: 31.88 (-0.12), SHLD: 15.00 (+0.04), AGN: 279.32 (-1.99), SBUX: 58.36 (-0.47), JACK: 63.12 (+0.02), JNJ: 108.31 (-0.19), DNKN: 45.32 (-0.21), IBM: 147.95 (+2.55), CMG: 471.37 (-3.09), ABBV: 56.12 (-0.24), SNY: 38.87 (-0.53), KKD: 14.61 (+0.32), REGN: 370.80 (+5.42), HD: 130.46 (+0.24), PFE: 30.08 (-0.11), LLY: 71.12 (-0.05), GSK: 39.56 (+0.19), BMY: 62.52 (+0.18), PLKI: 51.07 (+0.98), DIN: 92.00 (-1.02), CELG: 100.54 (+0.62), QSR: 37.63 (-0.38), GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), AZN: 28.00 (-0.01), MCD: 123.29 (-0.90), WEN: 10.42 (+0.06)
10 Women Who Would Be a Great Addition to Any Company's Board
at The Street - Thu Mar 24, 12:03PM CDT
Seven companies in the S&P 500 have no women on their boards. Maybe they're having trouble finding the right women? We aren't. Here are 10 that would make great additions.
CXO: 103.61 (+2.07), HST: 16.18 (unch), MDLZ: 39.51 (-0.43), HON: 111.32 (-0.89), CAH: 81.48 (+0.20), KORS: 55.53 (-0.40), IDA: 74.11 (+0.08), DO: 21.96 (+0.06), AMAT: 20.15 (-0.13), EOG: 74.30 (-0.04), MSFT: 54.21 (+0.24), REV: 35.99 (+0.50), MU: 10.50 (-0.15), HAR: 85.66 (+0.57), SWKS: 76.20 (-0.10), PFE: 30.08 (-0.11), MCHP: 48.12 (+0.16), LLTC: 44.26 (+0.14), UL: 44.63 (+0.03), MGM: 20.52 (-0.24), CELG: 100.54 (+0.62), GILD: 91.32 (+1.24), TXN: 56.70 (+0.10), MRK: 53.07 (-0.01), QLGC: 13.01 (+0.12), ADI: 58.64 (+0.31), MRO: 10.29 (+0.10), CVX: 94.85 (+1.26), XRAY: 59.62 (-0.93), NVS: 73.30 (-0.61), GRMN: 38.97 (-0.36), CCE: 49.59 (-0.21), K: 75.44 (+0.40), JNPR: 25.36 (-0.28), IBM: 147.95 (+2.55), APA: 48.85 (+0.99), GOOGL: 754.84 (-2.72), TER: 21.09 (+0.03), ALGN: 70.23 (+0.45), MET: 42.30 (-1.11), DISCA: 27.99 (+0.18), FCAU: 7.62 (-0.15), ISIL: 13.21 (+0.18), ORCL: 40.97 (+0.22), SQ: 12.88 (+0.29), GS: 153.00 (-1.08), QRVO: 49.24 (-0.28), LRCX: 78.88 (-0.48), BAX: 40.11 (-0.58), GM: 30.96 (-0.35), CRUS: 34.47 (-0.11), PG: 82.89 (+0.07), AVGO: 153.00 (+0.01), GSBD: 19.89 (unch), CRM: 72.44 (+0.66)
The 3 Best Stocks to Own in Retirement
Todd Campbell, Sean Williams, and Steve Symington, The Motley Fool - Motley Fool - Thu Mar 24, 10:03AM CDT
Image source: Pixabay. Retirees are living longer than ever before, and that means retirees are focusing their portfolios less on slow-growth Treasury bonds and more on stocks so they don't outlive their savings. While stocks can add some punch to...
PFE: 30.08 (-0.11), VZ: 53.56 (+0.65), AFL: 62.70 (-0.70)
Pfizer's Revised Filing for Xeljanz Accepted for Review in EU
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 9:20AM CDT
Pfizer (PFE) had resubmitted the Marketing Authorization Application (MAA) for Xeljanz, which was accepted for review by the European Medicines Agency.
EBS: 33.75 (+0.60), PFE: 30.08 (-0.11), AMAG: 21.42 (+0.74), ANIK: 44.00 (-0.74)
If It Wasn't For Pfizer, Allergan Investors Might Be Getting Pummeled
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:21AM CDT
SOURCE: FLICKR USER STOCKMONKEYS.COM The unraveling of its buy-reprice-relaunch strategy has led to shares in Valeant Pharmaceuticals crumbling 80% in the past year, but Valeant Pharmaceuticals is far from the only publicly traded biopharma...
AGN: 279.32 (-1.99), VRX: 31.09 (-2.34), PFE: 30.08 (-0.11), HZNP: 16.02 (-0.30), TEVA: 54.29 (+0.24), DEPO: 13.31 (+0.17)
Portola Pharmaceuticals' Betrixaban Misses Mark, But All Is Not Lost
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:14AM CDT
SOURCE: PORTOLA PHARMACEUTICALS Portola Pharmaceuticals ' 7,513 person head to head study evaluating its next-generation anticoagulant betrixaban against standard of care Lovenox in the prevention of blood clots missed its endpoint in one trial...
JNJ: 108.31 (-0.19), PTLA: 20.27 (-8.35), PFE: 30.08 (-0.11), BMY: 62.52 (+0.18), SNY: 38.87 (-0.53)
Allergan Is a Good Buy for Investors, With or Without Pfizer
at The Street - Thu Mar 24, 7:38AM CDT
The Irish pharmaceutical company is launching a blockbuster drug, and its share price seems primed for a rebound.
AGN: 279.32 (-1.99), PFE: 30.08 (-0.11)
Pfizer Announces European Medicines Agency Accepted for Review Its Marketing Authorization Application for XELJANZ(R) (Tofacitinib Citrate) for the Treatment of Moderate to Severe Rheumatoid Arthritis
Business Wire - Wed Mar 23, 3:15PM CDT
Pfizer Inc. (NYSE
FE) announced today that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for XELJANZ(R) (tofacitinib citrate) 5 mg tablets twice daily for the treatment of patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). The EMA will now initiate its review of the XELJANZ MAA. PFE: 30.08 (-0.11)
Follicular Thyroid Cancer - Pipeline Review, H1 2016 Featuring Exelixis, Inc., Genzyme Corporation, Novartis AG & Pfizer Inc. - Research and Markets
Business Wire - Wed Mar 23, 1:09PM CDT
Research and Markets (http://www.researchandmarkets.com/research/3v53qr/follicular) has announced the addition of the "Follicular Thyroid Cancer - Pipeline Review, H1 2016" report to their offering.
PFE: 30.08 (-0.11), NVS: 73.30 (-0.61), EXEL: 4.04 (+0.07)
Novartis Stock Downgraded: 3 Things You Need to Know
Rich Smith, The Motley Fool - Motley Fool - Wed Mar 23, 12:00PM CDT
With its stock down 26% in 52 weeks, German pharmaceutical giant Novartis is looking cheap and winning fans on Wall Street. But Leerink Partners is not one of them. According to data from S&P Global Market Intelligence , 16 out of 34...
JNJ: 108.31 (-0.19), PFE: 30.08 (-0.11), NVS: 73.30 (-0.61)
Stocks Run in Place as Brussels Attack Paralyzes Wall Street
at The Street - Tue Mar 22, 3:09PM CDT
A quieter holiday trading week was disrupted by tragedy on Tuesday, with dual explosions at a Brussels airport and metro station reigniting global concerns about terrorism.
VRX: 31.09 (-2.34), DAL: 47.84 (-1.07), PFE: 30.08 (-0.11), DB: 17.54 (-0.46), LL: 13.15 (+0.61), PCLN: 1,301.19 (-4.92), CELG: 100.54 (+0.62), UAL: 57.84 (-1.90), LUV: 44.06 (-0.37), GILD: 91.32 (+1.24), EXPE: 107.69 (-1.30), AAL: 40.50 (-1.42), AAPL: 105.67 (-0.46), IHG: 39.52 (+0.12)
Stock Market News for March 22, 2012
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 9:10AM CDT
Gains in healthcare and telecom stocks helped the benchmarks end marginally higher on Monday.
IHS: 119.57 (-1.43), FBHS: 54.56 (-0.09), PFE: 30.08 (-0.11), MRKT: 34.31 (+0.73), AMGN: 149.24 (+0.48), MAR: 68.64 (-0.96), HOT: 82.13 (-0.54), AGN: 279.32 (-1.99), T: 38.88 (+0.34), LEN: 46.35 (+0.15), GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), PHM: 17.91 (-0.07), OC: 47.00 (+0.30), VZ: 53.56 (+0.65)
Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts
Business Wire - Tue Mar 22, 9:00AM CDT
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 3, 2016. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2016 Performance Report, to be issued that morning.
PFE: 30.08 (-0.11)
Which Big Pharma Is the Best Dividend Stock?
Keith Speights, The Motley Fool - Motley Fool - Tue Mar 22, 8:12AM CDT
Image Source: LENDINGMEMO.COM . Big pharmaceutical firms have been a popular choice for dividend-seeking investors for a long time. Several pay out attractive and reliable dividends, and they throw in some opportunities for growth to boot. But...
PFE: 30.08 (-0.11), AZN: 28.00 (-0.01), ABBV: 56.12 (-0.24), GSK: 39.56 (+0.19), SNY: 38.87 (-0.53)
Pfizer Joins The Human Vaccines Project To Help Decode The Immune System
Business Wire - Tue Mar 22, 7:30AM CDT
Pfizer Inc. (NYSE
FE) today announced it will join the Human Vaccines Project (the Project), a public-private consortium focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection. Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV and other infectious illnesses as well as cancer. PFE: 30.08 (-0.11)
Why Amgen Is the Best S&P 500 Company
at The Street - Tue Mar 22, 7:24AM CDT
Bill Smead, chief investment officer and CEO of Smead Capital Management, sees opportunities in Amgen, which is his top holding.
JNJ: 108.31 (-0.19), GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), PFE: 30.08 (-0.11), AMGN: 149.24 (+0.48)
Celgene & Pfizer Present Data from Ulcerative Colitis Trials
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 12:20PM CDT
Celgene (CELG) and Pfizer (PFE) have presented data from their ulcerative colitis study at the 11th Congress of the European Crohn's and Colitis Organisation.
PFE: 30.08 (-0.11), HZNP: 16.02 (-0.30), ANIK: 44.00 (-0.74), CELG: 100.54 (+0.62)
SmarTrend Watching for Potential Pullback in Shares of Pfizer After 1.21% Gain
Comtex SmarTrend(R) - Mon Mar 21, 12:11PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.44 to a high of $29.87. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $29.65 on volume of 12.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PFE: 30.08 (-0.11)
After Yesterday's Rally of 1.21% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Mar 21, 12:09PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.44 to a high of $29.87. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $29.65 on volume of 12.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PFE: 30.08 (-0.11)
2 Large-Cap Dividend Favorites and 5 Stocks to Avoid Based on Charts
at The Street - Sun Mar 20, 11:00AM CDT
Recently, TheStreet highlighted Deutsche Bank's top large-cap dividend stocks from a fundamental perspective. Today in-house chartist Bruce Kamich takes a technical look.
CCI: 85.58 (-0.08), PFE: 30.08 (-0.11), IVZ: 30.33 (-0.07), WDC: 48.12 (-0.60), PLD: 42.32 (+0.14), HPQ: 12.07 (+0.05), CSCO: 27.96 (+0.13)
